Given the effects of NVB-mediated POLθ inhibition on PD-L1 expression and the interaction with anti-PD-1 blockade in HR repair-deficient cancers, we reasoned that the antitumor activity of NVB may depend on tumor cell-extrinsic responses in addition to the known cell-intrinsic mechanisms. The gene discussed is CD274; the disease is cancer.